Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BreastImmune03: Nivolumab and Ipilimumab in TNBC
NCT03818685Phase 2Active, not recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Jul 2019
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in triple-negative breast cancer (TNBC), sponsored by Centre Léon Bérard. Started Jul 2019; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03818685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818685.